Brad Wallace November 26, 2014 Toronto Company Leads International Team Developing Novel Vaccines Brad Wallace November 26, 2014 No, I haven't heard of them either. But that's not the point. These guys are doing good. Gotta love that. The goal of the project is to complete the pre-clinical development of the world’s first vaccines for respiratory syncytial virus (RSV) and parainfluenza type 3 (PIV3) virus, and ultimately a co-formulated combination vaccine. The project leverages a novel adjuvant which is designed to induce a powerful balanced immune response against a variety of viral and bacterial antigens. The development of vaccines against the two viruses would result in a significant health impact for Canada, China and the rest of the world, with over 800 million of the young and aged citizens especially at risk from these viruses.